MTOR and nonpapillary renal cell carcinoma: Given the distinct genetic differences between pRCC and ccRCC, it is not surprising that therapies targeting the vascular endothelial growth factor (VEGF) and the mammalian target of rapamycin (mTOR) have failed to benefit pRCC patients to the same extent as ccRCC patients 9.